PR.com: Business Directory, Press Releases, Jobs, Products, Services, Articles
 
Businesses Articles Press Releases Follow @PRcom
Press Release Pricing | News by Category | News by Country | News by US Region | Recent News | PR.com News on Your Site
 

Press Releases

 
DelveInsight

Press Release


Receive press releases from DelveInsight: By Email RSS Feeds:

Chimeric Antigen Receptor (CAR) T Cell Immunotherapy - Competitive Landscape, Technology and Pipeline Analysis, 2016


New Delhi, India, January 29, 2016 --(PR.com)-- DelveInsight, the leading market research and consulting company has added new report “Chimeric Antigen Receptor (CAR) T cell Immunotherapy - Competitive Landscape, Technology and Pipeline Analysis, 2016” to its portfolio.

CAR-T cells are the next targeted agents in Oncology. CAR-T cell therapy is a therapy in which T-cells from patient’s own immune system were removed from his own blood, genetically engineered to target his cancer, and then dripped back into his veins. Recent years have seen a dramatic increase in the development of certain CAR-T cell generations, which provides more target specificity These therapies have shown the enormous potential to treat B-cell hematologic malignancies and other cancer indications but, like the other face of the coin, the therapy also includes the adverse events of CRS, TLS and organ specific toxicities. Keeping in mind the adverse effects of CAR-T cells, companies are now developing safety switches. The CAR-T cells are being clubbed with safety switches to suppress CAR T cells if serious side effects emerge, or to make them self-destruct if they attack healthy tissue which is again giving a push to the big companies to invest in this sector.

Reports Highlights:
· CAR-T cell Therapy Pipeline scenario
· Collaborations & partnering deals
· Current Prominent Research Areas and Key Players
· Pipeline product profiles CAR-T Technologies and Targeted Antigens
· Licensing opportunities
· Market Drivers and Barriers

Report Coverage:
40+ companies, 100+ products and 24 different technologies

DelveInsight Report, “Chimeric Antigen Receptor (CAR) T cell Immunotherapy- Competitive Landscape, Technology and Pipeline Analysis, 2016” emphasizes on the currently active CAR-T cell products in research and development. The Report provides in-depth analysis on the CAR-T cell profiles covering pre-clinical and clinical studies, collaborations details and deal values, technologies and targeted antigens.

The Report provides the CAR-T licensing opportunities, acquisitions, market drivers and barriers followed by SWOT Analysis. Report also describes the unmet needs covered by CAR-T cells highlighting the adverse events, which are major concerns in the market for the usage of CAR-T cells.

This Report will help you to identify emerging players with potentially strong product information, licensing opportunities and helps you to create effective counter-strategies to gain competitive advantage.

DelveInsight is offering the Report at a price of USD 2,450 as a single user license, USD 4,900 as a site license and USD 7,350 as a Global/Enterprise License.

For more information on Pipeline Insight Reports, email at info@delveinsight.com

Contact Us:
DelveInsight Business Research
New Delhi-110075, India
Phone: +91-11-45689769, +91 9650213330
Website: http://www.delveinsight.com

About Us
DelveInsight is a leading Business Consulting and Market Research Firm. We help our clients to find answers relevant to their business, facilitating decision-making; identify potential market opportunities, competitor assessments and business environmental assessment. In addition to this DelveInsight also deals in providing custom research services in coherence with interest area of the clients.
Contact Information
DelveInsight
Ankush Gupta
+91-11-4568 9769
Contact
www.delveinsight.com

Click here to view the list of recent Press Releases from DelveInsight
Promote Your Business